Evaluation serum levels of Insulin Growth Factor-1 (IGF-1) and its association with clinical parameters in severe COVID-19
Background Severe coronavirus disease-2019 (COVID-19) is associated with dysregulated immune response and extreme inflammatory injury. Considering the role of insulin growth factor-1 (IGF-1) in immune-mediated and inflammatory reactions, this study was conducted to investigate the IGF-1 contribution...
Gespeichert in:
| Veröffentlicht in: | Inflammopharmacology 2022-02, Vol.30 (1), p.199-205 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 205 |
|---|---|
| container_issue | 1 |
| container_start_page | 199 |
| container_title | Inflammopharmacology |
| container_volume | 30 |
| creator | Feizollahi, Parisa matin, Somaieh Roghani, Seyed Askar Mostafaei, Shayan Safarzadeh, Elham Taghadosi, Mahdi |
| description | Background
Severe coronavirus disease-2019 (COVID-19) is associated with dysregulated immune response and extreme inflammatory injury. Considering the role of insulin growth factor-1 (IGF-1) in immune-mediated and inflammatory reactions, this study was conducted to investigate the IGF-1 contribution to the pathogenesis of severe form of COVID-19.
Material and methods
Sixty-two patients with severe COVID-19 and 52 healthy subjects were enrolled in this study. The serum levels of IGF-1 were measured using a solid-phase enzyme-linked chemiluminescent immunoassay on an Immulite 2000 system (Siemens Healthcare Diagnostics.
Result
The serum levels of IGF-1 had no significant difference in COVID-19 patients compared to the healthy subjects (
p
= 0.359). There was a positive correlation between IGF-1 and age in the severe COVID-19 patients, while a negative correlation was observed for the serum levels of IGF-1 and age in the control group (
r
= 0.364,
p
= 0.036,
r
= − 0.536,
p
= 0.001, respectively). Moreover, IGF-1 was remarkably associated with hypertension, neurogenic disease, shock, and nausea in patients with the severe form of COVID-19 (
p
= 0.031,
p
= 0.044,
p
= 0.01,
p
= 0.03, respectively).
Conclusion
Our results pointed to the complex role of IGF-1 in the severe form of COVID-19, and its association with clinical parameters, and some risk factors in the severe form of COVID-19. |
| doi_str_mv | 10.1007/s10787-021-00908-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_455853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2624201376</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-3972cea7fbd73d02a0879440b07acec657d5781caee78f388554315fe1ff3e603</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEotPCC7BAXpaF4TqOf7JBQkNnGKlSN8DW8jg3rUsSD3YyI3j6eshQ0Q0rWz7nfNf2KYo3DN4zAPUhMVBaUSgZBahBU_msWDAhNRUS9PNiAXUpaCXr8qw4T-keAKSS9cvijAuoNddyUfy-2ttusqMPA0kYp550uMcukdCSzZCmzg9kHcNhvCMr68YQKSOXm_WKsnfEDg3xYyI2peD8zDj47HQ55Z3tyM5G2-OIMRF_5O8xIlnefN98pqx-VbxobZfw9Wm9KL6trr4uv9Drm_Vm-emaukpXI-W1Kh1a1W4bxRsoLWhVVxVsQVmHTgrVCKWZs4hKt1xrISrORIusbTlK4BcFnbnpgLtpa3bR9zb-MsF6czr6kXdoKiG04Nn_cfZnpcfG4TBG2z2JPVUGf2duw95oDaxUOgMuT4AYfk6YRtP75LDr7IBhSqaUZVUC40pmazlbXQwpRWwfxzAwx5LNXLLJJZs_JZtj6O2_F3yM_G01G_jpxVkabjGa-zDFIX_y_7APDpyzxg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624201376</pqid></control><display><type>article</type><title>Evaluation serum levels of Insulin Growth Factor-1 (IGF-1) and its association with clinical parameters in severe COVID-19</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>SWEPUB Freely available online</source><creator>Feizollahi, Parisa ; matin, Somaieh ; Roghani, Seyed Askar ; Mostafaei, Shayan ; Safarzadeh, Elham ; Taghadosi, Mahdi</creator><creatorcontrib>Feizollahi, Parisa ; matin, Somaieh ; Roghani, Seyed Askar ; Mostafaei, Shayan ; Safarzadeh, Elham ; Taghadosi, Mahdi</creatorcontrib><description>Background
Severe coronavirus disease-2019 (COVID-19) is associated with dysregulated immune response and extreme inflammatory injury. Considering the role of insulin growth factor-1 (IGF-1) in immune-mediated and inflammatory reactions, this study was conducted to investigate the IGF-1 contribution to the pathogenesis of severe form of COVID-19.
Material and methods
Sixty-two patients with severe COVID-19 and 52 healthy subjects were enrolled in this study. The serum levels of IGF-1 were measured using a solid-phase enzyme-linked chemiluminescent immunoassay on an Immulite 2000 system (Siemens Healthcare Diagnostics.
Result
The serum levels of IGF-1 had no significant difference in COVID-19 patients compared to the healthy subjects (
p
= 0.359). There was a positive correlation between IGF-1 and age in the severe COVID-19 patients, while a negative correlation was observed for the serum levels of IGF-1 and age in the control group (
r
= 0.364,
p
= 0.036,
r
= − 0.536,
p
= 0.001, respectively). Moreover, IGF-1 was remarkably associated with hypertension, neurogenic disease, shock, and nausea in patients with the severe form of COVID-19 (
p
= 0.031,
p
= 0.044,
p
= 0.01,
p
= 0.03, respectively).
Conclusion
Our results pointed to the complex role of IGF-1 in the severe form of COVID-19, and its association with clinical parameters, and some risk factors in the severe form of COVID-19.</description><identifier>ISSN: 0925-4692</identifier><identifier>EISSN: 1568-5608</identifier><identifier>DOI: 10.1007/s10787-021-00908-6</identifier><identifier>PMID: 35098386</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Allergology ; Biomedical and Life Sciences ; Biomedicine ; COVID-19 ; Dermatology ; Gastroenterology ; Humans ; Immunology ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor I - metabolism ; Original ; Original Article ; Pharmacology/Toxicology ; Rheumatology ; SARS-CoV-2</subject><ispartof>Inflammopharmacology, 2022-02, Vol.30 (1), p.199-205</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-3972cea7fbd73d02a0879440b07acec657d5781caee78f388554315fe1ff3e603</citedby><cites>FETCH-LOGICAL-c484t-3972cea7fbd73d02a0879440b07acec657d5781caee78f388554315fe1ff3e603</cites><orcidid>0000-0002-3516-0130</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10787-021-00908-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10787-021-00908-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,551,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35098386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:148696563$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Feizollahi, Parisa</creatorcontrib><creatorcontrib>matin, Somaieh</creatorcontrib><creatorcontrib>Roghani, Seyed Askar</creatorcontrib><creatorcontrib>Mostafaei, Shayan</creatorcontrib><creatorcontrib>Safarzadeh, Elham</creatorcontrib><creatorcontrib>Taghadosi, Mahdi</creatorcontrib><title>Evaluation serum levels of Insulin Growth Factor-1 (IGF-1) and its association with clinical parameters in severe COVID-19</title><title>Inflammopharmacology</title><addtitle>Inflammopharmacol</addtitle><addtitle>Inflammopharmacology</addtitle><description>Background
Severe coronavirus disease-2019 (COVID-19) is associated with dysregulated immune response and extreme inflammatory injury. Considering the role of insulin growth factor-1 (IGF-1) in immune-mediated and inflammatory reactions, this study was conducted to investigate the IGF-1 contribution to the pathogenesis of severe form of COVID-19.
Material and methods
Sixty-two patients with severe COVID-19 and 52 healthy subjects were enrolled in this study. The serum levels of IGF-1 were measured using a solid-phase enzyme-linked chemiluminescent immunoassay on an Immulite 2000 system (Siemens Healthcare Diagnostics.
Result
The serum levels of IGF-1 had no significant difference in COVID-19 patients compared to the healthy subjects (
p
= 0.359). There was a positive correlation between IGF-1 and age in the severe COVID-19 patients, while a negative correlation was observed for the serum levels of IGF-1 and age in the control group (
r
= 0.364,
p
= 0.036,
r
= − 0.536,
p
= 0.001, respectively). Moreover, IGF-1 was remarkably associated with hypertension, neurogenic disease, shock, and nausea in patients with the severe form of COVID-19 (
p
= 0.031,
p
= 0.044,
p
= 0.01,
p
= 0.03, respectively).
Conclusion
Our results pointed to the complex role of IGF-1 in the severe form of COVID-19, and its association with clinical parameters, and some risk factors in the severe form of COVID-19.</description><subject>Allergology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>COVID-19</subject><subject>Dermatology</subject><subject>Gastroenterology</subject><subject>Humans</subject><subject>Immunology</subject><subject>Insulin-Like Growth Factor Binding Protein 3</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Original</subject><subject>Original Article</subject><subject>Pharmacology/Toxicology</subject><subject>Rheumatology</subject><subject>SARS-CoV-2</subject><issn>0925-4692</issn><issn>1568-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp9kc1u1DAUhSMEotPCC7BAXpaF4TqOf7JBQkNnGKlSN8DW8jg3rUsSD3YyI3j6eshQ0Q0rWz7nfNf2KYo3DN4zAPUhMVBaUSgZBahBU_msWDAhNRUS9PNiAXUpaCXr8qw4T-keAKSS9cvijAuoNddyUfy-2ttusqMPA0kYp550uMcukdCSzZCmzg9kHcNhvCMr68YQKSOXm_WKsnfEDg3xYyI2peD8zDj47HQ55Z3tyM5G2-OIMRF_5O8xIlnefN98pqx-VbxobZfw9Wm9KL6trr4uv9Drm_Vm-emaukpXI-W1Kh1a1W4bxRsoLWhVVxVsQVmHTgrVCKWZs4hKt1xrISrORIusbTlK4BcFnbnpgLtpa3bR9zb-MsF6czr6kXdoKiG04Nn_cfZnpcfG4TBG2z2JPVUGf2duw95oDaxUOgMuT4AYfk6YRtP75LDr7IBhSqaUZVUC40pmazlbXQwpRWwfxzAwx5LNXLLJJZs_JZtj6O2_F3yM_G01G_jpxVkabjGa-zDFIX_y_7APDpyzxg</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Feizollahi, Parisa</creator><creator>matin, Somaieh</creator><creator>Roghani, Seyed Askar</creator><creator>Mostafaei, Shayan</creator><creator>Safarzadeh, Elham</creator><creator>Taghadosi, Mahdi</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0002-3516-0130</orcidid></search><sort><creationdate>20220201</creationdate><title>Evaluation serum levels of Insulin Growth Factor-1 (IGF-1) and its association with clinical parameters in severe COVID-19</title><author>Feizollahi, Parisa ; matin, Somaieh ; Roghani, Seyed Askar ; Mostafaei, Shayan ; Safarzadeh, Elham ; Taghadosi, Mahdi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-3972cea7fbd73d02a0879440b07acec657d5781caee78f388554315fe1ff3e603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Allergology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>COVID-19</topic><topic>Dermatology</topic><topic>Gastroenterology</topic><topic>Humans</topic><topic>Immunology</topic><topic>Insulin-Like Growth Factor Binding Protein 3</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Original</topic><topic>Original Article</topic><topic>Pharmacology/Toxicology</topic><topic>Rheumatology</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feizollahi, Parisa</creatorcontrib><creatorcontrib>matin, Somaieh</creatorcontrib><creatorcontrib>Roghani, Seyed Askar</creatorcontrib><creatorcontrib>Mostafaei, Shayan</creatorcontrib><creatorcontrib>Safarzadeh, Elham</creatorcontrib><creatorcontrib>Taghadosi, Mahdi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Inflammopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feizollahi, Parisa</au><au>matin, Somaieh</au><au>Roghani, Seyed Askar</au><au>Mostafaei, Shayan</au><au>Safarzadeh, Elham</au><au>Taghadosi, Mahdi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation serum levels of Insulin Growth Factor-1 (IGF-1) and its association with clinical parameters in severe COVID-19</atitle><jtitle>Inflammopharmacology</jtitle><stitle>Inflammopharmacol</stitle><addtitle>Inflammopharmacology</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>30</volume><issue>1</issue><spage>199</spage><epage>205</epage><pages>199-205</pages><issn>0925-4692</issn><eissn>1568-5608</eissn><abstract>Background
Severe coronavirus disease-2019 (COVID-19) is associated with dysregulated immune response and extreme inflammatory injury. Considering the role of insulin growth factor-1 (IGF-1) in immune-mediated and inflammatory reactions, this study was conducted to investigate the IGF-1 contribution to the pathogenesis of severe form of COVID-19.
Material and methods
Sixty-two patients with severe COVID-19 and 52 healthy subjects were enrolled in this study. The serum levels of IGF-1 were measured using a solid-phase enzyme-linked chemiluminescent immunoassay on an Immulite 2000 system (Siemens Healthcare Diagnostics.
Result
The serum levels of IGF-1 had no significant difference in COVID-19 patients compared to the healthy subjects (
p
= 0.359). There was a positive correlation between IGF-1 and age in the severe COVID-19 patients, while a negative correlation was observed for the serum levels of IGF-1 and age in the control group (
r
= 0.364,
p
= 0.036,
r
= − 0.536,
p
= 0.001, respectively). Moreover, IGF-1 was remarkably associated with hypertension, neurogenic disease, shock, and nausea in patients with the severe form of COVID-19 (
p
= 0.031,
p
= 0.044,
p
= 0.01,
p
= 0.03, respectively).
Conclusion
Our results pointed to the complex role of IGF-1 in the severe form of COVID-19, and its association with clinical parameters, and some risk factors in the severe form of COVID-19.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>35098386</pmid><doi>10.1007/s10787-021-00908-6</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-3516-0130</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-4692 |
| ispartof | Inflammopharmacology, 2022-02, Vol.30 (1), p.199-205 |
| issn | 0925-4692 1568-5608 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_455853 |
| source | MEDLINE; SpringerLink Journals; SWEPUB Freely available online |
| subjects | Allergology Biomedical and Life Sciences Biomedicine COVID-19 Dermatology Gastroenterology Humans Immunology Insulin-Like Growth Factor Binding Protein 3 Insulin-Like Growth Factor I - metabolism Original Original Article Pharmacology/Toxicology Rheumatology SARS-CoV-2 |
| title | Evaluation serum levels of Insulin Growth Factor-1 (IGF-1) and its association with clinical parameters in severe COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A17%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20serum%20levels%20of%20Insulin%20Growth%20Factor-1%20(IGF-1)%20and%20its%20association%20with%20clinical%20parameters%20in%20severe%20COVID-19&rft.jtitle=Inflammopharmacology&rft.au=Feizollahi,%20Parisa&rft.date=2022-02-01&rft.volume=30&rft.issue=1&rft.spage=199&rft.epage=205&rft.pages=199-205&rft.issn=0925-4692&rft.eissn=1568-5608&rft_id=info:doi/10.1007/s10787-021-00908-6&rft_dat=%3Cproquest_swepu%3E2624201376%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2624201376&rft_id=info:pmid/35098386&rfr_iscdi=true |